Head-to-head · Cost-Efficiency Index
Kin Meds vs Bioverse
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Kin Meds
Shoppers modeling the real monthly cost before they commit.
Visit Kin MedsBioverse
Shoppers in one of Bioverse's 18 served states willing to prepay 6 months upfront for the lowest rate.
Visit BioverseThe verdict
Kin Meds takes it, leading the Cost-Efficiency Index 47 to 46. Kin Meds is a GLP-1 telehealth provider whose own website could not be accessed for live verification due to active bot-protection/CAPTCHA (confirmed via direct fetch, a text-rendering proxy, and live browser automation). Bioverse still earns a C — Shoppers in one of Bioverse's 18 served states willing to prepay 6 months upfront for the lowest rate.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Kin Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Kin Meds | Bioverse |
|---|---|---|
| Cost-Efficiency Index | 47/100 | 46/100 |
| Semaglutide / mo | Not disclosed | $129/mo (starting dose, prepay plan, compounded) |
| Tirzepatide / mo | Not disclosed | Not disclosed |
| Semaglutide / yr (modeled) | — | $1,548 |
| Tirzepatide / yr (modeled) | — | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Yes |
| Rank here | #447 | #452 |
Kin Meds
47/100Where the value is
- Appears to have an established web/social presence per search results
The tradeoffs
- Site is unreachable for independent verification behind active bot/CAPTCHA protection
- No pricing, medical director, or pharmacy partner could be confirmed directly from the company
Regulatory note: the FDA issued a warning letter to Kin Meds in February 2026. We still list and link to Kin Meds; you should know the letter is on the public record before you decide.
Bioverse
46/100Where the value is
- Established, well-reviewed GLP-1 telehealth brand
- Explicit, published list of 18 states served (transparent about limited coverage)
- LegitScript badge displayed on-site
The tradeoffs
- Headline 'starting at' price requires a full 6-month upfront prepayment -- not a real monthly rate
- Two different landing pages on the same domain advertise two different 'starting' prices ($99 vs $129) for what appears to be the same prepay structure
Regulatory note: the FDA issued a warning letter to Bioverse, Inc. dba Bioverse in September 2025. We still list and link to Bioverse; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.